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Although small molecules shed from pathogens are
widely used to diagnose infection, such tests have
not been widely implemented for tuberculosis. Here
we show that the recently identified compound, 1-tu-
berculosinyladenosine (1-TbAd), accumulates to
comprise >1% of all Mycobacterium tuberculosis
lipid. In vitro and in vivo, two isomers of TbAd
were detected that might serve as infection markers.
Using mass spectrometry and nuclear magnetic
resonance, we established the structure of the previ-
ously unknown molecule, N6-tuberculosinyladeno-
sine (N6-TbAd). Its biosynthesis involves enzymatic
production of 1-TbAd by Rv3378c followed by con-
version to N6-TbAd via the Dimroth rearrangement.
Intact biosynthetic genes are observed only within
M. tuberculosis complex bacteria, and TbAd was
not detected among other medically important path-
ogens, environmental bacteria, and vaccine strains.
With no substantially similar known molecules in na-
ture, the discovery and in vivo detection of two abun-
dant terpene nucleosides support their development
as specific diagnostic markers of tuberculosis.
INTRODUCTION
Tuberculosis (TB) remains a leading cause of death worldwide,
resulting in 1.5 million deaths annually (World Health Organiza-516 Chemistry & Biology 22, 516–526, April 23, 2015 ª2015 Elseviertion, 2014), yet no rapid, sensitive, and specific diagnostic test
exists. Diagnosis based on detection ofMycobacterium tubercu-
losis in patient samples mainly relies on sputum microscopy,
which is insensitive, or on in vitro culture, which is slow, insensi-
tive and infeasible in many clinics. T-cell antigen recall tests,
such as intradermal injection of purified protein derivative
(PPD) or interferon-g release assays (IGRA) are in widespread
use (Lalvani and Pareek, 2010) but give delayed results or are
expensive and have suboptimal test characteristics related
to sensitivity and specificity. Vaccination with live Bacille
Calmette-Gue´rin (BCG) in most parts of the world leads to anti-
gen-specific T-cell responses, which create false-positive re-
sults, rendering the PPD test unusable in many populations.
Accordingly, there is now strong consensus that developing
better diagnostic tests for M. tuberculosis infection is the key
issue for improved disease control through rapid initiation of
antibiotics and categorization of patients for vaccine trials (Hane-
kom et al., 2008).
Detection of pathogen-specific shed molecules or antigens
provides rapid and specific diagnosis of many infectious
diseases. Such antigen tests have long been a mainstay of diag-
nosis for infection by cryptococci, legionella, and other patho-
gens (Shelhamer et al., 1996). The strengths of antigen test
technology are high diagnostic specificity and rapid detection
of molecules using a simple ELISA of urine or serum (Couturier
et al., 2014). Therefore, the key criterion for discovery of chemi-
cal targets for antigen tests is specific expression of the target by
the disease-causing pathogen, combined with lack of expres-
sion among other microbes, especially those that are abundant
in the environment or cause diseases that mimic the disease of
interest. Other desirable criteria related to test sensitivity involveLtd All rights reserved
identifying targets with broad expression among most infecting
strains in clinical settings, expression of the antigen at high con-
centrations, expression in vivo under conditions of infection, and
lack of host degradation ormetabolism to unrecognizable chem-
ical forms.
In addition to antigen capture, pathogen-specific molecules
can be coated onto plastic and used to detect target-specific
host antibodies, functioning as a serological test. Such tests
have not yet moved into widespread clinical use for TB due in
part to specificity concerns that may be related to immune
responses to environmental mycobacteria, mildly pathogenic
mycobacteria, or live vaccine strains (Lawn et al., 2012) against
TB (Baumann et al., 2014).
Despite the widespread use of antigen and serological tests in
other infectious diseases, neither type of test is widely used for
TB. Although the urine lipoarabinomannan (LAM) ELISA has use-
fulness for TB-HIV coinfection (Lawn et al., 2012), no antigen or
serological test has emerged as having widespread clinical use-
fulness for tuberculosis. The current chemical targets for testing
were chosen based on their ready availability and represent only
a small fraction of the candidate small molecules that could be
developed. For example, among 169 subclasses of mycobacte-
rial lipids in the MycoMass and Lipid DB databases, more than
90% are expressed only by mycobacteria (Layre et al., 2011;
Sartain et al., 2011). Thus, the potential range of specific myco-
bacterial targets for diagnostics development is vast and largely
unexplored.
We initiated a comprehensive effort to discover specific
chemical targets for diagnostic testing using a newly developed
high-performance liquid chromatography (HPLC)-mass spec-
trometry (MS)-based lipidomics platform (Layre et al., 2011).
A recent comparative lipidomics screen of mycobacteria
sought to identify those molecules that are present in
M. tuberculosis but are lacking in a BCG vaccine strain (Layre
et al., 2014). These two species are evolutionarily related
and share more than 99% sequence identity but only
M. tuberculosis causes widespread disease. BCG has been
administered to more than 3 billion people and it induces
immune responses that can cause false-positive immuno-
logical tests for TB (World Health Organization, 2014). By
identifying cell wall lipids absent in BCG, we reasoned
that such molecules would also be lacking in BCG vaccines
and in other less related bacteria that confound the
diagnosis of TB. Also, given the lower infectious potential of
BCG, molecules selectively expressed in M. tuberculosis
might be virulence factors. This screen identified a previ-
ously unknown diterpene nucleoside, 1-tuberculosinyladeno-
sine (1-TbAd) (Layre et al., 2014).
Having established the lack of 1-TbAd in BCG, here we
sought to determine if 1-TbAd has the key test charac-
teristics needed for use as a diagnostic target, including high
abundance, specific expression, and shedding from intact
bacteria in ways that lead to detection in vivo. Unexpectedly,
we identified an abundant but previously unknown terpene
nucleoside derived from M. tuberculosis present in vivo. The
discovery of two terpene nucleosides, which are specifically
and abundantly expressed by M. tuberculosis, provides two
highly attractive targets for development for new diagnostic
tests for TB.Chemistry & Biology 22,RESULTS
1-TbAd Is a Major Lipid in M. tuberculosis
1-TbAd was identified in M. tuberculosis using an electrospray
ionization (ESI)-MS-based lipidomics platform. Among 7852
ions, 1-TbAd (C30H46N5O4
+; m/z 540.3545) was the second
most intense ion in the lipidome (Layre et al., 2014). The high in-
tensity might have resulted from 1-TbAd’s accumulation to high
concentration. Yet it was difficult to imagine that any abundant
class of molecule would have escaped detection over decades
of study of a pathogen of worldwide importance. Alternatively,
1-TbAd might have been present only in trace amounts, yet its
intrinsically charged nature and amphipathic character might
have promoted particularly efficient ionization in ESI-MS. To
measure the mass of 1-TbAd as a percentage of all lipid, we
analyzed extracts from M. tuberculosis strain H37Rv using the
method of standard additions. We compared the area under
the curve of retention time versus intensity measured at the
mass (m/z 540) of 1-TbAd (A540) and phosphatidylethanolamine
(A720), which controls for the efficiency of ESI-MS detection. As
with other polar lipids (Layre et al., 2011), we observed a nearly
linear relationship between mass input and 1-TbAd signal inten-
sity (Figure 1A). In three experiments, we determined that
1-TbAd comprises 1.1%, 1.4%, and 1.5% of mycobacterial
lipids. Thus, contrary to expectations that terpene nucleosides
previously escaped detection due to scarcity, 1-TbAd is a highly
abundant molecule that comprises a major class of lipid in
M. tuberculosis. The basis for lack of prior detection remains
unknown, but the near co-elution of 1-TbAd and abundant
membrane phospholipids in normal-phase thin-layer chroma-
tography and HPLC methods might have obscured 1-TbAd
detection in the past (Figure 1B).
Constitutive Biosynthesis of 1-TbAd
1-TbAd was initially isolated from bacteria grown in a formulated
rich medium (7H9) in late logarithmic phase (Layre et al., 2014).
Because rv3377c and rv3378c protect bacteria against low pH,
we reasoned that TbAd production might be pH responsive.
However, we detected equivalent production with high absolute
intensity (>106 counts) when growing at neutral (7.4) or lysosomal
pH (4.5) (Figure 1C). Furthermore, 1-TbAd production was not
substantially inhibited during the stationary phase, with labora-
tory strains of different origins (Layre et al., 2014), or when
growing in minimal (Sauton) or rich (7H9) medium (Figure 1D).
Thus, 1-TbAd is constitutively produced at high concentrations
among diverse in vitro conditions and we could not identify sig-
nals for its inhibition.
1-TbAd Biosynthetic Gene Expression
To function as a sensitive marker of infection, molecules must be
expressed in most strains of M. tuberculosis that infect patients
and among the seven recognized M. tuberculosis lineages that
exist worldwide (Comas et al., 2013). 1-TbAd derives from gera-
nylgeranyl pyrophosphate (GGPP) and adenosine, which are
present in nearly all organisms. Lipid cyclization and coupling
to adenosine are performed by specialized enzymes, Rv3377c
(prenyl cyclase) and Rv3378c (tuberculosinyl transferase), which
together with polyprenyl synthases comprise a functional gene
island (Mann and Peters, 2012) that is necessary and sufficient516–526, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 517
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Figure 1. 1-TbAd Is a Major Lipid in
M. tuberculosis
(A) M. tuberculosis was grown in 7H9 medium in
batches (experiments 1–3) and washed, extracted
into organic solvents and weighed (Lipid). Lipids
were spiked with 1-TbAD and subjected to posi-
tive-mode HPLC-Q-TOF-MS analysis to estimate
1-TbAd concentration.
(B) M. tuberculosis lipids were separated in
normal-phase silica thin-layer chromatography
or HPLC-MS, demonstrating near co-elution of
1-TbAd with abundant membrane phospholipids.
(C and D) M. tuberculosis grown in minimal (Sau-
ton) or complete 7H9 with albumin (A), oleic acid
(O), dextrose (D), and catalase (C) at the indicated
pH was subjected to lipid extraction and positive-
mode normal-phase HPLC-Q-TOF-MS. ADC,
albumin-dextrose-catalase; OADC, oleic acid-
albumin-dextrose-catalase.for 1-TbAd biosynthesis (Layre et al., 2014). Knowledge of the
essential TbAd biosynthetic genes allowed a survey of the
genomes of 432 phylogeographically diverse clinical isolates of
theM. tuberculosis complex (MTB complex) for an intact biosyn-
thetic locus. TbAd genes were detected among all clinical strains
examined.
We identified 25 unique single nucleotide polymorphisms
(SNPs) in rv3377c and 22 unique SNPs in rv3378c affecting a total
of 150M. tuberculosis strains (Table S1). While the proportion of
non-synonymous SNPs (nSNP) (18/25 in rv3377c vs 14/22 in
rv3378c) in bothgeneswassimilar,morestrains containednSNPs
in rv3377c (101strainswithnSNP in rv3377cversus52strainswith
nSNP in rv3378c). To understand the selection forces driving
rv3377c and rv3378c sequence diversity, we calculated the ratio
of the rates of non-synonymous to synonymous single nucleotide
changes (dN/dS) of both genes with respect to the inferred MTB
complex ancestor. The whole-gene dN/dS ranged from 0.97 to
0.47 for rv3377c and rv3378c, respectively. The dN/dS for
rv3378c was similar to the global dN/dS of the M. tuberculosis
genome (0.45–0.67) in MTB complex (Comas et al., 2010),
whereas the dN/dS of rv3377c was significantly higher.
Bioinformatic algorithms that seek to identify which mutations
are likely to alter protein function suggested that 60% (15/25) of
nSNPs identified in rv3377c are not likely to affect protein struc-
ture (Table S1). However, ten SNPs are predicted to have notable
effects on structure. The replacement of a glycine at position 31
with a valine is predicted to affect the protein structure in the
entire lineage 6, also known as M. africanum. In summary, we
found that most clinical isolates have an intact rv3377c-3378c
locus and no clear evidence for selection driving the mutations
identified, with the exception that lineage 6 might have an inac-
tivating mutation.518 Chemistry & Biology 22, 516–526, April 23, 2015 ª2015 Elsevier Ltd All rights reservedPathogen-Specific Gene
Expression
To determine whether 1-TbAd biosyn-
thesis exists in species other than
M. tuberculosis, we sought orthologs of
rv3377c and rv3378c across the biolog-
ical kingdoms. Confirming a prior analysis(Mann and Peters, 2012), few candidate orthologs were found
among non-mycobacterial species. Low stringency searches
did return candidate rv3378c orthologs in Zeamays andDictyos-
telium discoideum. However, considering all non-mycobacterial
species, we did not identify candidate orthologs organized into a
locus with both essential genes present. Among mycobacteria,
orthologs of rv3377c and rv3378c could not be identified
in most species, including disease-causing members of the
M. avium complex, M. kansasii, and M. marinum (Figure 2A).
Instead, orthologs were present only within the MTB complex:
in M. bovis, M. bovis BCG (Pasteur strain), M. cannetti, and
M. africanum. However, coding mutations were found in the
locus in all species other thanM. tuberculosis as detailed in Fig-
ure 2A. Two mutations were found in the Pasteur strain of BCG
(Pasteur), including a frameshift mutation that is likely inactivat-
ing (Figure 2A). Thus, we could not identify an intact orthologous
locus outside the MTB complex and we found a wild-type
sequence only in M. tuberculosis.
However, gaps in the analysis remained. Some but not
all of the rv3378c mutations, including those present in
M. africanum, have been proven to inactivate lipid biosynthesis
(Chan et al., 2014; Layre et al., 2014). Second, BCG vaccine
strains are of particular interest because they cause false-posi-
tive immunological tests. Although the locus in BCG strain Pas-
teur was inactivated through frameshift, other BCG or M. bovis
strainsmight never have acquired thesemutations, or theymight
have done so and then reverted to wild-type sequences. The 12
widely used BCG vaccine strains show variations in efficacy (Ritz
et al., 2008), so differential expression of TbAdmight account for
this (Pethe et al., 2004). However, further analysis of all common
vaccine strains used worldwide (Pasteur, Copenhagen, Japan,
Mexican, Australian, Russia, Glaxo, Prague, Phipps, Connaught,
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Figure 2. Genetic and Biochemical Analysis of TbAd Biosynthetic
Genes, rv3378c, rv3377c, and 1-TbAd in Lung Pathogens, Environ-
mental Mycobacteria, and Vaccine Strains
(A) The TbAd locus encodes a geranylgeranyl pyrophosphate cyclase
(Rv3377c) and tuberculosinyl adenosine transferase (Rv3378c). Orthologous
Chemistry & Biology 22,Denmark, Tice) confirmed the presence of the frameshift muta-
tion in all cases, so 1-TbAd is likely absent from all major vac-
cines used worldwide.
1-TbAd Expression in Pathogens
A general limitation of genetic analysis is that genes might exist
that are functionally equivalent to rv3377c and rv3378c but lack
the sequence identity needed for identification as orthologs.
Therefore, we undertook biochemical analysis for 1-TbAd
production, focusing on non-tuberculous mycobacteria and
microbes, whose infection can mimic tuberculosis disease. By
adapting the existing HPLC-MS lipidomics protocol (Layre
et al., 2011), we validated a rapid method to specifically detect
1-TbAd within complex lipid mixtures. Analyzing total lipids,
molecular events (linked intensity, m/z, and retention time
values) corresponding to all lipids are recorded and the events
corresponding to the mass (m/z 540.35) and retention time
(23min) of authentic 1-TbAd are reported (Figure 2B). Monitoring
of unfractionated lipids avoids time-consumingmethods needed
to purify 1-TbAd, as well as artifacts introduced through sample
handling. Datasets can be subjected to further data mining for
events corresponding to other lipid products that are upstream
and downstream in biosynthetic pathways, isomers of 1-TbAd,
as well as TbAd variants with defined changes in mass due to
chain length variation or oxidation. Initial validation showed
that no other mycobacterial lipid obscured the event corre-
sponding to the mass and retention time (tR) of 1-TbAd. Further-
more, total lipid extracts of the human THP-1 macrophage-like
cell line did not generate detectable signals at this mass and tR
coordinate, even when amplified 1000-fold (Figure 2B, inset).
Thus, no host lipid interfered with TbAd detection in this system,
which is a key consideration for diagnostic applications.
Lipid extracts from non-actinomycete bacteria (Escherichia
coli, Staphylococcus aureus) and fungi (Aspergillis fumigatus,
Candida albicans) did not produce a 1-TbAd signal. Turning to
mycobacteria, we could not detect 1-TbAd among reference
strains of environmental (M. fallax) or non-pathogenic laboratory
strains of mycobacteria (M. smegmatis, M. phlei) that lack
rv3378c orthologs (Figure 2C). In agreement with the genetic re-
sults, we did not detect 1-TbAd among disease-causing bacteria
that are related toM. tuberculosis but lack identifiable orthologs
of rv3377c-3378c (M. avium, M. marinum) or those with orthol-
gous loci containing a known frameshift mutation (M. bovis).
Among all organisms tested to date, only M. tuberculosis pro-
duces 1-TbAd.
Detection of 1-TbAd In Vivo
To determine if 1-TbAd is detectable in vivo, we infected BALB/c
mice via inhalation for 21 days followed by collection of whole-
lung homogenates. Target validation in vivo does not require
scanning of the complete lipidome, but instead focuses on
sensitive and specific detection of predetermined targets,
which are likely to be highly diluted within host tissues.We devel-
oped a reversed-phase method to increase chromatographicgenes are shown by arrows and SNPs are indicated by vertical lines. Table S1
lists polymorphisms for these genes in the M. tuberculosis complex.
(B and C) Lipid extracts from human macrophage-like cells (THP-1),
M. tuberculosis H37Rv, or the indicated species were subjected to HPLC-MS.
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Figure 3. Detection of 1-TbAdExVivo inMice alongwith a Previously
Unknown Diterpene Nucleoside
(A) Reversed-phase, triple quadrupole HPLC-MS analysis of tissue extracts
from mice infected with M. tuberculosis with ion monitoring at m/z 540.4
detected a peak at 11.7 min that was identified as 1-TbAd based on near co-
elution with an authentic 1-TbAd standard (not shown) and the diagnostic
transitions (540/ 408/ 136) characteristic of 1-TbAd. Another peak with the
same mass at 14.1 min demonstrates transitions that are not seen in 1-TbAd
including 540/ 148. Results are representative of six experiments in which
both ions were detected in all cases.
(B) Separate experiments conducted on in vitro grownM. tuberculosis H37Rv
analyzed in normal-phase HPLC-Q-TOF-MS likewise identified two terpene
nucleoside isomers, with the late-eluting form matching the retention time of
1-TbAd. Separate analysis of cell-associated and shed lipids were accom-
plished by extraction of cell pellets and conditioned supernatants. CID-MS
analysis confirmed the expected ions for the late-eluting 1-TbAd isomer.
520 Chemistry & Biology 22, 516–526, April 23, 2015 ª2015 Elsevierresolution, while taking advantage of the specificity and accu-
racy of triple quadrupole mass detection. This method detected
a 1-TbAd standard at 11.8 min based on its known transition for
1-TbAd (m/z 540 / 408 / 136). Direct analysis of unfractio-
nated lipids from whole-lung homogenates did not detect signal
corresponding to 1-TbAd in uninfected lung but did detect a
signal corresponding to 1-TbAd that was well above background
signals in six of six infectedmice tested, with representative data
shown in Figure 3A. Thus, 1-TbAd is produced in vivo and is
readily detected ex vivo in a one-step HPLC-MS method.
Unknown Terpene Nucleoside
Ion chromatograms of the ion 540/ 408 also showed a second,
later-eluting peak (14.6 min) with transitions that were distinct
from 1-TbAd in all six mice tested (Figure 3A). Unlike 1-TbAd,
the unknown lipid contained a 540 / 148 ion and a relatively
bright 540 / 408 transition that was equivalent in intensity to
the 540/ 136 ion. Returning to normal-phase HPLC-quadru-
pole time-of-flight (Q-TOF)-MS experiments using in vitro grown
M. tuberculosis, ion chromatograms measured atm/z 540.4 also
showed two peaks at 25 and 7 min, which corresponded to
late-eluting 1-TbAd and an early-eluting unknown lipid detected
in mice (Figure 3B). Collision-induced dissociation (CID)-MS
analysis of the unknown showed fragment ions of m/z 148.062
and 408.313, matching the pattern of the late-eluting unknown
from reversed-phase chromatography, suggesting that they
were the samemolecule (Figures 3A and 3C). Thus, the unknown
later-eluting compound detected in mice was likely derived from
M. tuberculosis rather than the host. Also, separate tracking of
the unknown and 1-TbAd in the bacterial pellet and conditioned
supernatant demonstrated a much higher ratio of signal for the
unknown in supernatants (Figure 3B). Thus, the early-eluting un-
known was likely generated during or after transit from the
cytosol to the extracellular space.
1-TbAd Isomers
The unknown (m/z 540.355) and 1-TbAd (m/z 540.3545, calcu-
lated) had identical molecular ion masses (±2 ppm) and similar
fragmentation patterns. The unknown had a much lower reten-
tion time in normal-phase chromatography. Therefore, the un-
known was likely a much less polar isomer of 1-TbAd. CID-MS
ions were assigned unequivocally as C5H6N5
+ (m/z 136.0618)
and C10H14N5O4
+ (m/z 268.1040), matching the mass of adenine
and adenosine, respectively. The neutral loss leading to m/z
268.1040 suggested the loss of C20H32, likely a diterpene moiety
(Figure 3B). A fragment ion with the formula C25H38N5 (calculated
m/z 408.3122) matches the loss of a pentose-derived fragment
(C5H8O4, calculated 132.0423 Da). Therefore, the unknown
was a diterpene-substituted adenosine (C30H45N5O4).
Experiments were guided by two hypotheses. The unknown
isomer and 1-TbAd might differ in the type of diterpene carried,
or a tuberculosinyl group could have an alternate linkage to
adenine. M. tuberculosis produces geranylgeranyl (GG) pyro-
phosphate and tuberculosinyl pyrophosphate is hydrolyzed
to isotuberculosinol in vitro (Nakano et al., 2011). Therefore,CID-MS of the unknown detected ions consistent with a diterpene adenosine
structure, but bright ions at m/z 408.31, 148.06 were seen only in the early-
eluting isomer (unknown).
Ltd All rights reserved
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Figure 4. NMRAnalysis of theUnknown Iso-
mer Establishes the Structure of N6-tuber-
culosinyladenosine
(A) The alternative diterpene hypothesis predicts
compounds that 1-TbAd and the unknown isomer
might differ in the identity of the diterpene coupled
to generate 1-geranylgeranyladenosine or 1-iso-
tuberculosinyl adenosine, which are depicted as
candidate structures. Alternatively, the unknown
isomer could be generated by coupling adenosine
to tuberculosinol at the N6 position of adenine to
generate N6-TbAd.
(B) N6-Geranylgeranyladenosine was synthesized
to provide a 6-linked NMR standard, which is
analyzed with the unknown in Data S1 and S2.
BOP, (benzotriazol-1-yloxy)tris(dimethylamino)
phosphonium hexafluorophosphate; DEAD, di-
ethyl diazenedicarboxylate; DIBAL, diisobutylalu-
minum hydride; DIPEA, ethyldiisopropylamine;
DMF, N,N-dimethylformamide; HMPA, hexame-
thylphosphoramide; THF, tetrahydrofuran.
(C) NMR (Bruker 800 MHz) of the unknown and
standard shows upfield shifts, relative to 1-TbAd
(Layre et al., 2014), in the protons of the tuber-
culosinyl group closest to adenine. These are
accounted for by the absence of a positive charge
on adenine in the N6-TbAd. The unknown also
compares well in this spectral region with N6-(3-
methyl-2-butenyl)adenosine. The resonances
from the tuberculosinyl side chain positions 1400
and 1500 (labeled with a and b in the correspond-
ing N6-(3-methyl-2-butenyl)adenosine spectrum)
adjacent to the heterocyclic adenine moiety are
shifted similarly, relative to 1-TbAd, due to the
positive to neutral charge shift.
(D) The presence of the m/z 148 fragment in N6-
TbAd results from charge-directed fragmentation
after protonation of a double bond that can occur
with the N6-TbAd but not the analogous 1-TbAd.1-GGAd and 1-isoTbAd were candidate structures (Figure 4A).
However, they would be expected to have largely the same ionic
properties as 1-TbAd. Alternatively, a tuberculosinyl linkage at
the N6 adenosine position would mimic common N6-linked
adenine compounds including zeatin (Heyl et al., 2012) and
would be expected to alter the ionic properties observed in
the unknown. Therefore, we considered N6-tuberculosinylade-
nosine as a candidate structure (Figure 4A) and we synthesized
N6-(E,E,E)- andN6-(E,E,Z)-geranylgeranyl-adenosine as amodel
N6-linked compound to evaluate this hypothesis (Figure 4B;
Data S2).
Identification of N6-TbAd
Detection of the isomer in cultured M. tuberculosis provided
a route to purifying it in greater quantity. After growing
M. tuberculosis cultures in roller bottles, 50 mg of lipid was
fractionated by normal-phase open-column chromatography
followed by reversed-phase HPLC. Adding 0.2% trifluoroacetic
acid (TFA) to the mobile phase increased the retention of
1-TbAd in reversed-phase chromatography but did not affect
the unknown isomer, confirming that the two compoundsChemistry & Biology 22,differed in their ionic properties. This purification sequence pro-
duced  300 mg of each isomer so that the combined yield
(1.2%) confirmed ESI-MS studies (Figure 1A).
Analysis of the MS data and 1H correlated spectroscopy
(COSY), nuclear Overhauser effect spectroscopy (NOESY), and
heteronuclear multiple-quantum correlation (HMQC) nuclear
magnetic resonance (NMR) spectra (800 MHz) (Table 1) estab-
lished the structure of the unknown as N6-TbAd. A 1-linked ger-
anylgeranyl side chain could not produce signals as low as the
observed signals at 1 ppm. The single vinylic proton H14
00
would
be replaced by the two H15
00
protons in the isotuberculosinyl
group, ruling out this possibility. The spectral data for 1-TbAd
andN6-TbAd (Table 1) both correspond closely to those of tuber-
culosinol (Nakano et al., 2005, 2011; Nakano and Hoshino, 2009;
Hoshino et al., 2011) except for the expected difference in the
side chain protons and carbons. The H-1700 methyl doublets at
d 0.85 and H-2000 methyl singlets at d 0.65–0.66 are particularly
characteristic of the tuberculosinyl ring system.
In the unknown, the signals of the adenosine moiety and the
side chain protons (H-1200 to H-1600) correspond closely to those
of N6-(3-methyl-2-butenyl)adenosine (Casati et al., 2010, 2011;516–526, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 521
Table 1. NMR Analysis
Atom Carbon 13 Hydrogen COSY NOESY
2 * 8.24
8 141.3 8.26 10
10 90.8 5.95 (d,6.6) 20 8,200
20 75.3 4.74 (dd,6.6,5.0) 10,30 10,30
30 72.4 4.32 (dd,5.0,2.6) 20,40 20,50
40 88.0 4.17 (ddd,2.6,2.4,2.4) 30,50,50 50,50
50 63.3 3.89 (dd,12.6,2.4) 40,50 40
3.75 (dd,12.6,2.4) 40,50 30,40
1a00 28.4 1.77 100,200,200 100,200,1000
1b00 1.04 100,200,200 100,2b00,2000
2a00 23.0 1.62 100,100,300,300 100,300,1900
2b00 1.62 100,100,300,300 100,300
3a00 41.8 1.41 300,200,200 200,1800,1900
3b00 1.21 (ddd,13.1,13.1,4.8) 300,200,200 200,1800
600 117.2 5.48 700,700,1000 700,700,1800
7a00 32.5 1.86 (br d,17.3) 600,700,800 600,700,800,1700
7b00 1.77 600,700,800 600,700,1600,1700,2000
800 34.3 1.54 700,700,1700 700,700,1000,1700
1000 40.9 2.25 (br d,12.9) 100,100,600 200,700,1000,1200,1900
1100 35.8 1.58 1100,1200,1200 800,1000,1200,1600,1700,2
1.42 1100,1200,1200 800,1000,1200,1600,1700,2
1200 33.7 2.00 1100,1100,1200 1000,1100,1100,1400,1600
1400 120.5 5.42 1200,1500,1600 1200,1200
1500 39.3 4.22–4.16 1400 1400,1600
1600 16.8 1.80 1200,1500
1700 15.2 0.85 (d,6.7) 800 700,700,800,1100,1100,2000
1800 30.0 1.06 300,300,600,1900
1900 29.3 1.02 200,300,1000,1800
2000 16.4 0.65 100,700,1100,1700
The combination of 1-D and 2-D NMR data lead to the determination of the side group structure as a tuberculosinyl group in N6 linkage, defining
N6-TbAd. Detailed spectra are shown in Data S1. The expected COSY and NOESY cross peaks are seen within the terpene, base and sugar fragments.
The only NOESY cross peak between the three fragments is between H10 and H8. The allylic methylene peak from the two H1500 protons is broad rather
than the expected doublet due to slow rotation about the C6-N bond. *, not observed.Ottria et al., 2010). The adenine protons at d 8.24 (H-8) and 8.26
(H-8) are characteristic of an N6-substituted adenosine and are
different from those of 1-TbAd at d 8.53 and 8.66. All COSY
and NOESY correlations are consistent with the assignment of
the unknown asN6-TbAd. The absorption of the allylic methylene
group is a broad peak at 4.22–4.16 ppm due to slow rotation at
room temperature around the C-N6 bond (Uzawa and Anzai,
1988). The diagnostic ion atm/z 148 in the N6-TbAd is explained522 Chemistry & Biology 22, 516–526, April 23, 2015 ª2015 Elsevierby an alternate protonation of the double bond at C-1400 and sub-
sequent charge-directed fragmentation, which would be sup-
pressed in 1-TbAd, having its positive charge stabilized in the
adenine ring (Figure 4D).
Dimroth Rearrangement of 1-TbAd to N6-TbAd
A plausible mechanism to account for the biological origin of
N6-TbAd is that 1-TbAd converts to N6-TbAd by a DimrothLtd All rights reserved
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Figure 5. A Two-Step Mechanism for N6-TbAd Biosynthesis
(A) The Dimroth rearrangement represents a specific and plausiblemechanism
that accounts for the rearrangement from cationic 1-linked adenosine to
neutral N6-linked adenosine compounds. The pKa values are derived from
analogous compounds and illustrate that only the 1-linked form is predomi-
nantly charged.
(B) Incubation of recombinant Rv3378c, tuberculosinyl pyrophosphate, and
adenosine yielded a strong signal for the 1-TbAd isomer (24 min) but no
detectable signal at the retention time for N6-TbAd (8 min).
(C) 1-TbAd was treated with dimethylamine in methanol to effect the conver-
sion (Ottria et al., 2010). MS3 analysis of the reaction products detected the
diagnostic fragment ion for N6-TbAd at m/z 148.2.
(D) Lung lipids were spiked with 1-TbAD, extracted for lipid and analyzed using
normal-phase HPLC-Q-TOF-MS under conditions that detect both isomers.
Chemistry & Biology 22,rearrangement, which involves attack of a nucleophile (such
as hydroxide or an amine) at C-2 to form a ring-opened interme-
diate followed by ring closure by the unsubstituted nitrogen to
give the N6-linked form (Figure 5A) (El Ashry et al., 2010; Fujii
and Itaya, 1998; Grimm and Leonard, 1967; Leonard et al.,
1966; Macon and Wolfenden, 1968; Ottria et al., 2010; Snyder
and Adams, 2011). Products from recombinant Rv3378c
enzyme showed a strong signal for 1-TbAd and no signal for
N6-TbAd, demonstrating that the latter is not a primary product
of this enzyme (Figure 5B). Furthermore, we observed that treat-
ing 1-TbAd under conditions known to favor the Dimroth reaction
(Me2NH in methanol) led to clean conversion into N
6-TbAd
(Figure 5C).
The pKa of the conjugate acid ofN
6-(3-methylbut-2-enyl)aden-
osine and of the 1-(3-methyl-2-butenyl) adenosine cation are
3.76 and 8.47, respectively (Martin and Reese, 1968). Thus, the
markedly differing chemical and physical properties of 1-TbAd
and N6-TbAd arise from their differing charge states, and they
predict differing responses to altered pH within the physiological
range. At neutral pH, N6-TbAd should exist as the neutral free
base, explaining why it is uncharged and elutes more readily
from normal-phase columns (Figures 5A and 5B). 1-TbAd is pre-
dominantly charged (protonated) at this pH and binds tightly to
polar silica gel and diol-modified stationary phases.
The data suggest a two-step model of biosynthesis whereby
Rv3378c mediates conjugation of tuberculosinyl pyrophosphate
and adenosine to produce 1-TbAd in the cytosol and 1-TbAd
could later rearrange to N6-TbAd in other compartments (Fig-
ure 3B). However, in vivo transformation of 1-TbAd to N6-TbAd
in mice could not be unequivocally established because mouse
lung analysis required harvest, homogenization, and HPLC-MS
analysis at the bench. The ex vivo workup of lung might have
inadvertently induced Dimroth rearrangement but this possibility
was ruled out by workup of lung spiked with 1-TbAd, which de-
tected only 1-TbAd (Figure 5D). In summary, Rv3378c produces
1-TbAd, which is transformed to N6-TbAd by the Dimroth rear-
rangement, and both compounds occur in vivo and represent
specific markers of M. tuberculosis infection (Figure 5E).
DISCUSSION
These studies show that 1-TbAd and the newly identified in vivo
biotransformation product, N6-TbAd, possess key features of
high-quality targets for development in antigen capture diag-
nostic or serological tests. These features include abundant
expression and efficient shedding, as well as absence of expres-
sion in common sources of false-positive test results including
vaccine strains, non-mycobacterial lung pathogens, and envi-
ronmental bacteria. Furthermore, these studies provide evi-
dence for intact biosynthetic genes among clinical strains and
expression by reference strains under many different conditions
surveyed, suggesting that it could be a sensitive biochemical
marker of infection. Taking advantage of the broad lipidomics
detection methods, the data demonstrate sensitive detection
of both TbAd isomers without interference by any other host,(E) These data support a two-step model in which 1-TbAd is the predominant
or sole product of Rv3378c followed by conversion to N6-TbAd, which can
occur during export of 1-TbAd to the extrabacterial space.
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bacterial, or fungal lipids using a standardized and simple HPLC-
MS test.
Another criterion for use of shedmolecules as diagnostic tools
is that they remain intact during in vivo infection or, if they are
metabolized by the host, generate recognizable transformation
products that are distinct from all host molecules. These data
identify the complete structure of N6-TbAd as a previously un-
known in vivo biotransformation product of M. tuberculosis.
Here we report a small proof-of-principle study in which both
TbAd isomers are readily detected in the lung. Starting from a
systematic screen of all M. tuberculosis-specific compounds,
these two terpene nucleosides meet all the criteria needed for
entry into human population studies.
Furthermore, these data determined the origin and stepwise
appearance of the TbAd isomers in ways that add to a basic un-
derstanding of tuberculosis pathogenesis. Prior studies by Pethe
et al. (2004) identified that Rv3378c acts by some unknown
mechanism to inhibit phagosomal acidification and promote
mycobacterial survival in macrophages. Rv3378c is localized in
the bacterial cytosol and yet might act in some way on events
in the phagosomal space. Our results identify the product of
Rv3378c as an amphipathic diterpene nucleoside (Layre et al.,
2014) and show that the product of Rv3378c is efficiently ex-
ported to the extracellular space, so that this product does
escape to the phagosomal compartment that is involved in pH
regulation. Unexpectedly, 1-TbAd undergoes biotransformation
to N6-TbAd, a previously unknown in vivo metabolite within the
infected host.
1-TbAd and N6-TbAd show only one difference in structure
but the site of tuberculosinyl linkage determines their pKa and
charge state. Quantitative consideration of the ionic properties
of 1-TbAd (pKa = 8.5) and N
6-TbAd (pKa = 3.8) (Kapinos et al.,
2011) predict that N6-TbAd is neutral at pH 7.4, whereas
1-TbAd exists as a mixture of [TbAd] and [TbAdH]+. During
active infection, M. tuberculosis typically grows in moderately
acidic phagosomal compartments or extracellular caseous
material. Therefore, 1-TbAd would change in charge states as
it leaves the neutral pH environment of the mycobacterial cell
wall, traverses the acidic phagosome, and enters the neutral
environment of infected tissues and finally the peripheral circu-
lation. These effects would alter its water solubility and adher-
ence to anionic membranes in the three compartments.
Furthermore, the Dimroth rearrangement is favored under basic
conditions. At lower pH, the concentration of nucleophiles de-
creases so 1-TbAd is less prone to rearrangement in the acidic
environment of localized acute infection. Thus, 1-TbAd has an
intrinsic chemical feature that would stabilize its structure while
in the phagosome and the N6-form might be more efficiently
generated in non-acid compartments that are distant from the
site of infection. In this scenario, 1-TbAd is more important in
control of the export to the phagosome and N6-TbAd might
represent an altered, possibly inactivated, form of 1-TbAd
whose importance derives its role as a recognizable infection
marker.
These studies set the stage for human population studies
to detect both TbAd isomers as targets for diagnosis in
clinically assayable fluids such as sputum, serum, and urine.
Both isomers are readily detected ex vivo using a routine
liquid chromatography-MS method. For serological applica-524 Chemistry & Biology 22, 516–526, April 23, 2015 ª2015 Elseviertions, the difference in charge state strongly predicts differing
host antibody responses to 1-TbAD and N6-TbAd, and knowl-
edge of these differing ionic properties may guide separate
development of these terpene nucleosides as targets for
ELISAs in the future. Although LAM ELISAs have emerged as
a clinical test with some utility, one limiting factor for this and
other mycobacterial lipid-specific ELISAs is thought to be
false-positive results from subclinical exposures to non-tuber-
culous mycobacteria or BCG vaccination (Baumann et al.,
2014; Lawn, 2012). Here we demonstrated the lack of
both TbAd isomers and the rv3377c-3378c genes in common
sources of false-positive immune response. These discovery-
based chemical studies open two new paths to the develop-
ment of simple and specific antigen or serological tests, which
are urgently needed for better care of patients and vaccine
research.
SIGNIFICANCE
The discovery and detection of 1-tuberculolsinyladenosine
and its rearrangement product N6-tuberculosinyladenosine,
produced in vivo during the course of mycobacterial infec-
tion in a murine model, provides unique chemical markers
to diagnose tuberculosis disease.
EXPERIMENTAL PROCEDURES
Bacteria Cultures
M. tuberculosis was grown in the absence of detergent in 7H9 medium
supplemented with 10% albumin-dextrose-catalase or oleic acid-albumin-
dextrose-catalase or in Sauton’s medium until mid-log phase with or without
phosphate-citrate buffers adjusted at the given pH. Supernatant was sepa-
rated from bacteria by centrifugation at 2000 3 g and filtration of supernatant
cultures (0.2 mm). Cell-associated or secreted lipids were extracted using suc-
cessive contact in chloroform and methanol mixtures or ethyl acetate, respec-
tively, as previously described (Layre et al., 2011).
Purification of 1-TbAd and the Unknown TbAd Isomer
Lipids were prepared by serially extracting desiccated or wet pellets ofMyco-
bacterium tuberculosisH37Rv and other named species with 1:2 (v/v), 1:1, and
then 2:1 chloroform/methanol. The combined extractswere dried at room tem-
perature and stored in 1:1 chloroform/methanol solution (10mg/ml). Fifty mil-
ligrams was concentrated under nitrogen resulting in a slurry that was loaded
on an open silica gel column (2 cm 3 1.6 cm). Lipids were eluted with 10 ml
of solvent in the following sequence: chloroform, chloroform/isopropanol
(95:5, v/v), chloroform/isopropanol (90:10, v/v), and chloroform/methanol
(50:50, v/v). Fractions were monitored for ions with a nominal m/z of 540 and
the m/z 540 / m/z 408 / m/z 148 transitions in the nanospray MS2 and
MS3, with the m/z 148 ions seen in the unknown (N6-TbAd), not 1-TbAd.
N6-TbAd eluted using isopropanol/chloroform while 1-TbAd required meth-
anol/chloroform for elution. After evaporation, 1-TbAd and its isomer were
further purified using reversed-phase HPLC using an octadecyl-modified silica
(5 mm) semi-preparative column (2503 10 mm) run under isocratic conditions
at 3.0 ml/min. 1-TbAd was purified using 89.9:10:0.2 (v/v/v) methanol/water/
trifluoroacetic acid monitoring by UV at 260 nm. Collected fractions were
evaporated to dryness in 0.5-ml portions with 2.0 ml of acetonitrile added to
help minimize exposure of the collected 1-TbAd to TFA. N6-TbAd was purified
using 5:90:5 chloroform/methanol/water (v/v/v) as the mobile phase, moni-
tored by UV at 260 nm, and eluted at.14.5 min.
Ion Trap MS
Multistage CID-MS experiments were completed on a linear ion trap (Thermo
Scientific LXQ) using a nanoelectrospray ionization source and borosilicate
glass pipettes pulled to a 2-mm tip.Ltd All rights reserved
Basic Dimroth Conversion
1-TbAd was converted to N6-TbAd by dissolving a small portion of 1-TbAd in
2 M dimethylamine in methanol at room temperature for 3 days.
NMR Analysis
A Bruker Avance 800 NMR instrument was used to analyze samples dissolved
in deuterated methanol (0.5 mg/ml) that were compared with a 1-TbAd stan-
dard (Layre et al., 2014).
HPLC-ESI-Q-TOF Analyses
Extracted cell-associated or secreted lipids were concentrated under reduced
pressure at room temperature. One hundred micrograms were resuspended
at 0.5 mg/ml in 70:30 hexane/isopropyl alcohol and 20 ml were injected for
analysis by HPLC-ESI-MS (Agilent 6520 QToF) as described (Layre et al.,
2014).
Reversed-Phase HPLC-MS
Mouse (BALB/c) lungs were harvested after 3 weeks and analyzed using an in-
jection volume of 50 ml using a reversed-phase, linear gradient elution method
developed using a Zorbax Eclipse Plus-C18 column (2.1 mm 3 50 mm,
3.5-mm particle size; Agilent Technologies). The solvents were (A) 0.1% formic
acid in milliQ water and (B) 0.1% formic acid in acetonitrile. After equilibration
for 8min with 100% solvent (0.2ml/min), a two-part linear solvent gradient was
used as follows: 0–10min, 0% to 100% solvent B; 10–22min, 100% to 0% sol-
vent B. Mouse experiments were conducted under oversight of the Animal
Ethics Subcommittee of the University of Kwazulu-Natal (protocol 107/13).
N6-TbAd Structural Analysis
Synthesis of N6-linked adenosine analogs and detailed descriptions of N6
products are described in the Supplemental Experimental Procedures.
Genetic Analysis of rv3377c and rv3378c
Detection of SNPs in rv3377c and rv3378c was done from multiple alignments
of the orthologous sequences of both genes retrieved from the genomes of
431 strains representative of the seven main phylogenetic lineages of the
MTB complex, comprising 271 published genomes (Comas et al., 2010), 161
whole genomes that are currently being analyzed, and 12 published BCG
strains (Copin et al., 2014). Nucleotides differing between the query strains
and the reference strain (Comas et al., 2010) were recorded as SNPs. The
genetic diversity of rv3377c and rv3378c in the MTB complex was done by
multiple alignments of the orthologous sequences of both genes retrieved
from the genome of 432 strains. CODEML from PAML 3.14b (Yang, 1997)
was used to estimate dN/dS rates. The codon frequencies were derived
from the average nucleotide frequencies at the three-codon position (F3 3 4
model), and the model was chosen to compute one ratio of dN/dS fixed for
all sites (model = 1 and NSsites = 0). The dN/dS was calculated using their
orthologous sequences in the most recent common ancestor as previously
described (Comas et al., 2010). To predict the impact of amino acid changes
on protein function, we used three algorithms in parallel: Sift (http://sift.jcvi.
org/), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), and Provean
(http://provean.jcvi.org/index.php).
Lipid Extracts of Microbial Species
The chloroform/methanol extraction and sources of mycobacterial, non-
mycobacterial, and fungal species used has been described (Ly et al., 2013).
In addition, M. marinum, C. albicans, and A. fumigatus were obtained from
the American Type Culture Collection.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Data S1 and S2, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.03.015.
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